S&P 500 7559.45 +0.21%
NASDAQ 26226.06 +0.07%
TASI 10808.43 -0.42%
Oil (WTI) 71.59 -0.68%
Oil (Brent) 76.06 -0.31%
VIX 15.59 -1.58%
Gold 4112.90 -0.67%
USD/SAR 3.75 +0.01%

Intellia Therapeutics, Inc.

NTLA · Healthcare · · USD
14.61 USD
0.00 (-5.38%)
● Updated 2026-07-10 17:11 Saudi Time ↻ Refresh
Short-term Mid-term Long-term

Fahodi Score BUY Short-term (Swing)

69
/ 100
Technical 75
Trend & RS 66
Momentum 72
Fundamental (0%) 22
Macro 71
Liquidity 23
ComponentScoreWeight
Technical 75.0 40%
Trend & RS 66.1 20%
Momentum 71.9 20%
Fundamental 22.2 0%
Macro 71.2 15%
Liquidity 23.1 5%

Trade Setup

Entry 14.95
Stop Loss 12.47 (16.6%)
Target 1 (1:1) 17.43 (+16.6%)
Target 2 (2:1) 19.91 (+33.2%)
ATR(14) 1.24 (8.3%)
Risk per Share 2.48
Reward:Risk 2:1

ATR-based levels. Adjust for support/resistance zones.

Factor Profile

Factor Score Z Bar
Value 75.4 +1.02
Momentum 71.9 +0.88
Quality 40.0 -0.40
Composite 62.4

Quality Scores

Piotroski F-Score 2 /9 — Weak
✗ ✗ ✗ ✗ ✓ ✓ ✗ ✗ ✗
1. Positive Net Income 2. Positive Roa 3. Positive Cfo 4. Quality Earnings 5. Lower Leverage 6. Higher Liquidity 7. No Dilution 8. Higher Gross Margin 9. Higher Asset Turnover
Altman Z-Score Insufficient Data

Valuation vs Peers Undervalued

MetricStockSectorvs Peers
P/E Ratio N/A 22.0 Inline
P/B Ratio 2.8 4.0 Below

Comparing against Healthcare median multiples.

Trading at a discount to sector peers — potential value opportunity.

Position Sizing — Kelly Criterion

4.8%
Recommended Size
45.38%
Full Kelly
22.69%
Half Kelly
5.0%
Max Cap (Moderate)

Kelly inputs derived from quant score 69/100. Estimated win rate 61%, avg win 9.2%, avg loss 3.6%. Position was capped at the moderate risk maximum. This is analytical output, not a recommendation to trade.

RECOVERY Regime: RECOVERY (20% confidence) — position size reduced 4%

Signal Summary STRONG BUY

3
Bullish Signals
1
Bearish Signals
46.27
RSI(14)
0.6604
MACD

Relative Strength (RS) WEAK RS

15
/ 99
RS Rating
O'Neil filter: <80
RS vs SPY ↑ RISING (-3.0% vs SPY 3M)
RS vs Sector OUTPERFORMING (Healthcare)
RS New High No (4d since high)
Sector Outperformance +4.6% (3M)
RS Line — stock / SPY (90 bars)
← older newer →
RS vs SPY 50-day SMA of RS
WEAK RS: Underperformer — the stock is lagging the market. Avoid until RS trend reverses upward.

Technical Indicators

IndicatorValueSignal
Rsi 46.27 NEUTRAL
Macd 0.6604 BEARISH
Ma Cross 14.29 / 13.73 GOLDEN CROSS
Trend Short ABOVE SMA50
Trend Long ABOVE SMA200
Bollinger MIDDLE
Volume 0.21x LOW

Key Levels

LevelPrice
52-Week High28.25
Bollinger Upper18.83
SMA(200)13.73
SMA(50)14.29
SMA(20)15.74
Current Price14.61
Bollinger Lower12.66
52-Week Low7.95
ATR(14)1.24

Advanced Technical Analysis

Click to expand

Wyckoff Phase & Volume Spread Analysis

Wyckoff Phase

DISTRIBUTION A Confidence
60%
Volume Dry-Up (Accumulation) Buying Climax
Acc: 2.0  |  Dist: 3.0  |  Markup: 0.0  |  Markdown: 0.0

Volume Spread Analysis (last 5 bars)

DateSignalVolDescription
2026-07-06 Normal 0.6x Normal bar — no special VSA pattern
2026-07-07 Normal 0.5x Normal bar — no special VSA pattern
2026-07-08 No Supply 0.55x Low volume, narrow spread, firm close — no selling pressure
2026-07-09 Normal 1.15x Normal bar — no special VSA pattern
2026-07-10 Normal 0.21x Normal bar — no special VSA pattern

Ichimoku Cloud NEUTRAL

LineValueStatus
Tenkan-sen (9) 16.52 Above Kijun
Kijun-sen (26) 15.14 Base line
Senkou A 15.83 Leading span A
Senkou B 15.12 Leading span B
Cloud 15.12 – 15.83 Bullish (Green)
Price vs Cloud 14.95 Below Cloud
Chikou Span 13.02 Bullish
Alignment Score 3/4 NEUTRAL

TTM Squeeze & Divergences

TTM Squeeze

SQUEEZE OFF No squeeze Momentum: BEARISH
BB: 12.66 – 18.83  |  KC: 13.82 – 17.67

Divergences (last 60 bars)

TypeIndicatorBars AgoStrength
Hidden Bearish RSI 29

Anchored VWAP

VWAP: 13.02 Anchor: 2025-11-20 (52w Low) ABOVE AVWAP +14.8%

Heikin-Ashi Trend

BEARISH Full data via /api/advanced/NTLA

Valuation

MetricValue
Market Cap2.04B
P/E (TTM)N/A
Forward P/EN/A
P/B2.83
EPS-3.52

Financial Health

MetricValue
Revenue Growth-9.5%
Profit MarginN/A
ROE-56.3%
Debt/Equity12.96
Current Ratio6.10
Dividend YieldN/A
Payout RatioN/A
Beta1.77

Trading Data

14.61
Open
14.61
Day High
14.61
Day Low
891.9K
Volume (0.1x avg)

Recent News (8)

Intellia Therapeutics (NTLA) Could Be 37% Undervalued After Phase 3 Lonvo Z Success
Simply Wall St. · 2026-07-09
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Zacks · 2026-07-09
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns
Simply Wall St. · 2026-07-09
Wall Street Doubles Down on Wolfspeed Short Positions Over Cash Burn Fears
Barchart · 2026-07-08
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Motley Fool · 2026-07-08
Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?
Insider Monkey · 2026-07-03
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Motley Fool · 2026-07-01
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Zacks · 2026-06-29

Price Chart (90 Days)

Candlesticks (green=up, red=down) SMA 20 SMA 50 Bollinger Bands (upper/lower) Volume (green=buying, red=selling)
Powered by Fahodi Methodology. This is analytical output, not financial advice. Always do your own due diligence.  ·  Pipeline status  ·  Data: —